Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Zeta Global Holdings Corp (ZETA) Price & Performance

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.

Zeta Global (ZETA) trades at $33.80, up 0.87% today, showing strong momentum with seven consecutive quarters of earnings beats. The stock exhibits a bullish technical setup with moving averages supporting the uptrend, though RSI levels suggest potential overbought conditions. Revenue growth accelerated to $1.3 billion in 2025 with improving margins, while analyst consensus remains strongly positive with 76% buy ratings and a $37.09 price target. Recent expansion into the UK market and AI platform adoption continue to drive investor optimism.

ZETA presents a compelling growth story with accelerating revenue and expanding customer base, though negative net margins and elevated valuation multiples warrant caution. The stock's proximity to 52-week highs combined with strong institutional support suggests continued upside potential, but investors should monitor margin improvement and competitive pressures in the AI marketing technology space.